http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Provention Bio to Present at the SVB Securities Global Biopharma Conference
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®
-
AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio Inc. (PRVB) Appoints Rita Jain to its Board
-
Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio's (PRVB) TZIELD Approved by FDA to Delay Onset of Stage 3 Type 1 Diabetes
-
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with St
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio Inc. (PRVB) to Combine Forces with Sanofi (SNY) to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes
-
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
-
Provention Bio Announces Senior Leadership Addition
-
Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital
-
Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio Inc. (PRVB) Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022
-
Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio to Present at the Jefferies Global Healthcare Conference
-
Provention Bio Inc. (PRVB) Announces Board Changes
-
Provention Bio Announces Update to Board of Directors
-
Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year
-
Provention Bio Inc. (PRVB) Reports Q1 Results, Provides Business Update
-
Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio Inc. (PRVB) Reports Positive Final Results from Study of Coxsackievirus B Vaccine Candidate PRV-101
-
Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
-
Provention Bio Inc. (PRVB) Announces FDA Acceptance of the BLA Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals
-
Provention Bio Announces FDA Acceptance of the Biologics License Application (BLA) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals
-
Provention Bio Announces the Grant of Inducement Awards
-
Provention Bio to Present at Two Upcoming Virtual Investor Conferences
-
Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
Provention Bio Inc. (PRVB) Announces BLA Resubmission for Teplizumab to Address CRL
-
Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL)
-
Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
-
Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference
-
Provention Bio Announces the Grant of Inducement Award
-
Provention Bio Inc. (PRVB) is Resubmitting BLA for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA
-
Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA